GlobeNewswire Inc.··NaHumacyte Scales Symvess Sales 400% as Leadership Bolsters Commercialization Push
Humacyte reports Q1 2026 revenue of $0.5M, up from $0.1M year-over-year, while appointing new commercial leaders and securing international orders for bioengineered blood vessels.
HUMAHUMAWPhase 3 clinical trialFDA approval